Projects per year
Projects
Search results
-
Active
-
First-in-human (FIH), open-label, phase 1 dose escalation study of ADG126 in patients with advanced malignancies
Richardson, G. & Lai, L. H.
11/03/21 → 31/12/24
Project: Research
-
A randomised, open-label phase 3 study of combination amivantamab and carboplatin-pemetrexed therapy, compared with carboplatin-pemetrexed, in patients with EGFR Exon 20ins mutated locally advanced or metastatic non-small cell lung cancer (PAPILLON)
Richardson, G. & Lai, L. H.
1/03/21 → 31/12/24
Project: Research
-
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer [MARIPOSA].
Richardson, G. & Lai, L. H.
26/02/21 → 31/12/23
Project: Research
-
Treatment for a poor prognosis subset of estrogen receptor breast cancers.
Mitchell, C., McLean, C., Loi, S. & Richardson, G.
1/01/21 → 31/12/23
Project: Research
-
MIRASOL: A randomised, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression
Richardson, G. & Lai, L. H.
30/11/20 → 31/12/22
Project: Research
-
A Phase 1b Study of ZN-c3 in Combination with Chemotherapy in Patients with Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer.
Richardson, G. & Baker, E.
22/10/20 → 31/12/22
Project: Research
-
An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU- 201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults with Non-Small Cell Lung Cancer [IMU201-101].
Richardson, G. & Baker, E.
14/10/20 → 31/12/22
Project: Research
-
A phase 1, open-label, dose escalation study of ADG116 in patients with advanced/metastatic solid tumors [ADG116-1003].
Richardson, G. & Baker, E.
24/09/20 → 31/12/23
Project: Research
-
An open label Phase 1B dose finding study of BI 836880 in combination with BI 754091 to characterise safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous non-small cell lung cancer and in other solid tumours.
Richardson, G. & Baker, E.
1/07/20 → 31/12/22
Project: Research
-
An open label Phase 1B dose finding study of BI 836880 in combination with BI 754091 to characterise safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous non-small cell lung cancer and in other solid tumours.
Richardson, G. & Baker, E.
3/06/20 → 31/12/22
Project: Research
-
Measuring adherence to best practice guidelines for the management of ovarian cancer in Australia to determine the extent to which variation in care influences clinical and patient-reported outcomes
Zalcberg, J., Rome, R., Antony, J., Schofield, P., Brand, A., Richardson, G., Farrell, R., Evans, S., Hegarty, S. & Earnest, A.
Department of Health (Australia)
1/06/20 → 31/05/25
Project: Research
-
Open-label Phase 2 study of Ladiratuzumab Vedotin (LV) for unresectable locally advanced or metastatic solid tumors [SGNLVA-005]
Richardson, G. & Baker, E.
13/05/20 → 31/12/21
Project: Research
-
A Phase I, Multi-center, Open-label, Dose Escalataion Study of CS3005 in Subjects with Advanced Solid Tumors
Richardson, G. & Baker, E.
5/03/20 → 31/12/22
Project: Research
-
A phase 1/2, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of AGEN2034 in subjects with metastatic or locally advanced solid tumors, with expansion to second line cervical cancer [C-700-001].
Richardson, G. & Baker, E.
10/09/19 → 31/12/24
Project: Research
-
A phase 1a/1b multicenter, open-label, dose escalation, dose expansion study evaluating the safety, pharmacokinetics and activity of GDC-9545 alone or in combination with palbociclib and/or LHRH agonist in patients with locally advanced or metastatic estrogen receptor-positive breast cancer [GO39932].
Richardson, G. & Baker, E.
24/05/19 → 31/12/24
Project: Research
-
A phase 1 study to evaluate the safety and tolerability of immunotherapy combinations in participants with advanced malignancies [AB928CSP0005].
Richardson, G. & Baker, E.
28/02/19 → 31/12/24
Project: Research
-
A phase 1/1b study to evaluate the safety and tolerability of immunotherapy combinations in participants with breast or gynaecologic malignancies [AB928CSP0002].
Richardson, G. & Baker, E.
28/02/19 → 31/12/24
Project: Research
-
A phase 1/1b study to evaluate the safety and tolerability of immunotherapy combinations in participants with gastrointestinal malignancies [AB928CSP0003].
Richardson, G. & Baker, E.
28/02/19 → 31/12/24
Project: Research
-
Combating adaptive resistance to tageted therapy in triple-negative breast cancer
Nguyen, L., Swarbrick, A., Richardson, G., Loi, S. & Daly, R.
15/02/19 → 14/02/23
Project: Research
-
A phase 1b/2 study of BMS-813160 in combination with chemotherapy or Nivolumab in patients with advanced solid tumors [CV202-103].
Richardson, G. & Baker, E.
10/12/18 → 31/12/24
Project: Research
-
A phase 1a/1b study of FPT155 in patients with advanced solid tumours [FPT155-001].
Richardson, G. & Baker, E.
10/12/18 → 31/12/23
Project: Research
-
Finished
A randomized, open-label, multicenter, phase 3 study to evaluate the efficacy and safety of Avelumab in combination with chemotherapy followed by maintenance therapy of Avelumab in combination with the poly (adenosine diphosphate [Adp] - ribose) polymerase (Parp) inhibitor talazoparib in patients with previously untreated advanced ovarian cancer (JAVELIN OVARIAN PARP 100) [B9991030]
Richardson, G. & Baker, E.
4/12/18 → 31/12/20
Project: Research